Seeking Alpha

In a move to shore up the commercial potential of Vascepa to beyond its patent expiry date of...

In a move to shore up the commercial potential of Vascepa to beyond its patent expiry date of 2030, Amarin (AMRN -0.7%) says it submitted a Supplemental New Drug Application to the FDA seeking approval for Chemport, Inc. as an additional Vascepa active pharmaceutical ingredient supplier. The submission is part of the company's goal to expand and protect its manufacturing supply chain.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|